| Ying Huang |
Ying Huang is currently the Chief Executive Officer & Director at Legend Biotech Corp. and the Director at Quanta Therapeutics, Inc. Previously, Dr. Huang worked as the Managing Director & Head-Biotech Equity Research at BofA Securities, Inc., a Research Analyst at Credit Suisse Securities (USA) LLC (Broker), a Principal Scientist at Schering-Plough Corp., an Associate Analyst at Wachovia Securities LLC, a Vice President & Senior Analyst at Barclays Capital, Inc., a Research Analyst at Merrill Lynch, Pierce, Fenner & Smith, Inc., and a Research Analyst at Gleacher & Co. Securities, Inc. Dr. Huang holds a graduate and doctorate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Science & Technology of China. |
| Mythili Koneru |
Mythili Koneru is currently the Chief Medical Officer at Legend Biotech Corp. Prior to this, she was the Chief Medical Officer at Marker Therapeutics, Inc. from 2019 to 2023. She also worked as an Associate Vice President-Immuno-Oncology at Eli Lilly & Co. from 2015 to 2019. Koneru received her undergraduate degree from The University of Chicago and her doctorate from New York University and Robert Wood Johnson Medical School. |
| Lori Macomber |
Lori Macomber is currently the Chief Financial Officer at Legend Biotech Corp. She previously worked as the Business Unit Controller at AMETEK, Inc. from 2018 to 2019, the Assistant VP-Finance Site Leader at Eli Lilly & Co. from 2010 to 2017, and the Controller & Chief Financial Officer-US Region at Cello Health Ltd. from 2017 to 2018. Ms. Macomber obtained her undergraduate degree from The Pennsylvania State University. |
| Lida Pacaud |
Currently, Lida Pacaud occupies the position of Vice President-Clinical Development at Legend Biotech Corp.
She previously held the position of Head-Global Clinical Program at Novartis International AG.
Dr. Pacaud received a doctorate from Tbilisi State Medical University. |
| Guo Wei Fang |
Guo Wei Fang is currently the Chief Scientific Officer at Legend Biotech Corp. Prior to this, he held the position of Head-Discovery at Pharmacyclics LLC and Senior Vice President-Research at Zymeworks BC, Inc. He completed his undergraduate degree at Nanjing University and obtained his doctorate from the University of Colorado Boulder. |
| Liz Gosen |
Liz Gosen is currently the Senior Vice President-Global Technical Operations at Legend Biotech Corp. Prior to this, she worked as the Vice President-Biologics Operations at Eli Lilly & Co. Ms. Gosen completed her undergraduate degree at Lehigh University and earned an MBA from Seton Hall University. |
| Tracy Luo |
Tracy Luo has worked as the Vice President of Clinical Development for Greater China at Legend Biotech Corp since 2018. |
| Ye Wang |
Ye Wang founded GenScript Corp. in 2002, where she is working as Chief Operating Officer & Executive Director from 2002 and Genscript Biotech Corp. in 2002, where she is working as President, COO & Executive Director. Ms. Wang also currently works at CustomArray, Inc., as Director, GenScript (Hong Kong) Ltd., as Director, Bestzyme Biotech Corp., as Director, Bestzyme Biotech Ltd., as Director, Bestzyme Biotech USA, Inc., as Director, Legend Biotech Corp., as Director from 2022, Legend Biotech Ltd., as Director, Genscript Biotech Ltd., as Director, GenScript International Ltd., as Director, GenScript USA, Inc., as Director, Maplebio Nanjing Co. Ltd., as Director, Probio Technology Ltd., as Director, Ren-Shiu Foundation, Inc., as President & Trustee, and Nanjing Genbest Enterprise Management Center, as Partner. Ms. Wang received her undergraduate degree in 1990 from Wuhan University, graduate degree in 1993 from Wuhan University, graduate degree in 2003 from the University of Bridgeport, and Masters Business Admin degree in 2014 from China Europe International Business School. |
| Fang Liang Zhang |
Fang Liang Zhang is the founder of GenScript Corp. (founded in 2002) and Genscript Biotech Corp. (founded in 2002). He currently holds the position of Chairman at Legend Biotech Corp. and Director at GenScript (Hong Kong) Ltd. He is also an Executive Director at Genscript Biotech Corp. and holds director positions at Nanjing Jinsirui Biotechnology Co., Ltd., Jinsikang Technology (Nanjing) Co., Ltd., Nanjing Bestzyme Bioengineering Co., Ltd., Hubei Bestzyme Biotechnology Co. Ltd., Shanghai Jingrui Biotechnology Co. Ltd., Bestzyme Biotech Corp., Bestzyme Biotech Hk Ltd., Bestzyme Biotech Ltd., Bestzyme Biotech USA, Inc., Nanjing Legend Biotechnology Co., Ltd., Legend Biotech HK Ltd., Legend Biotech Ltd., Genscript Biotech Ltd., GenScript International Ltd., and GenScript USA, Inc. His former positions include Chairman & Chief Executive Officer at Nanjingjinsirui Science & Technology Biology Corp., Director at Legend Biotech Corp. (2020), and Principal Scientist at Schering-Plough Holdings Ltd. (2002). Dr. Zhang obtained a doctorate degree from Duke University in 1995, a graduate degree from Nanjing University in 1987, and an undergraduate degree from Chengdu University of Technology in 1984. |
| Wai Man Yau |
Wai Man Yau is currently an Independent Director at Legend Biotech Corp., Chief Financial Officer & Executive Director at AMTD Strategic Capital Group, Chief Financial Officer at C. & J. Clark International Ltd., and a Member of the Hong Kong Institute of Certified Public Accountants. Previously, he held positions as Managing Director at Protiviti Shanghai Co. Ltd., Chief Financial Officer & Director at AMTD IDEA Group, Independent Non-Executive Director at China General Education Group Ltd., Senior Manager at PricewaterhouseCoopers LLP (Hong Kong), Partner at Ernst & Young (China), and Senior Manager at Arthur Andersen & Co. (Hong Kong). He holds an MBA from The Hong Kong University of Science & Technology and an undergraduate degree from Lundquist College of Business (conferral date: 1997). |
| Li Mao |
Li Mao is an Independent Director at Legend Biotech Corp. and the Chief Medical Officer at SciClone Pharmaceuticals (China) Co. Ltd. He was previously the Chief Executive Officer at Xcovery Holding, Inc. and the Director, Chief Medical Officer & SVP at Betta Pharmaceuticals Co., Ltd. He also served as the Chief Medical Officer at Sino Biopharmaceutical Ltd. Dr. Mao was a Professor at The University of Texas M.D. Anderson Cancer Center from 2004 to 2009 and at the University of Maryland Baltimore County from 2009 to 2016. He holds a doctorate degree from Nanjing Medical University. |
| Corazon Dating Sanders |
Corazon Dating Sanders is currently serving as a Director at AbGenomics International, Inc. Additionally, Sanders holds the position of Independent Director at Ultragenyx Pharmaceutical, Inc., Independent Non-Executive Director at BeiGene Ltd., Independent Director at Legend Biotech Corp., Independent Director at Molecular Templates, Inc., and Director at Altrubio, Inc. Previously, Sanders worked as a Director at Fred Hutchinson Cancer Research Center and Transcelerate Biopharma, Inc. Sanders also held the position of Senior Vice President & Global Head-PD Innovation at Genentech, Inc. From 2017 to 2018, Sanders served as the Executive Vice President-Development Operations at Juno Therapeutics, Inc.Sanders completed undergraduate and graduate studies at the University of the Philippines. Sanders also obtained graduate and doctorate degrees from The Wharton School of the University of Pennsylvania. |
| Patrick J. Casey |
Patrick J. Casey is currently an Independent Director at Legend Biotech Corp. and a Professor at Duke University. He previously served as Senior Vice Dean-Research at Duke University Health System, Inc., Assistant Professor at Duke University Medical Center, and Member-Governing Board at Research Centre of Excellence in Mechanobiology. He was also a Senior Vice Dean-Research at Duke-NUS Graduate Medical School Singapore. In the past, he worked as the Director of Duke University Center For Chemical Biology. Dr. Casey received his undergraduate degree from Augustana University and his doctorate from Brandeis University in 1986. |
| Tomas Jan Heyman |
Tomas Jan Heyman is currently the Chief Executive Officer at Interlaken Therapeutics, Inc. He also holds positions as Chairman at Venatorx Pharmaceuticals, Inc., Director at Exelixis, Inc., Independent Director at OptiNose, Inc., Director at Interuniversitair Micro-Electronica Centrum VZW, Independent Director at Legend Biotech Corp., Independent Director at Xilio Therapeutics, Inc., Independent Director at Akero Therapeutics, Inc., and Independent Director at Invivyd, Inc. In the past, Heyman served as Chairman & Chief Executive Officer at Janssen Pharmaceutica NV, Global Head-Business Development at Johnson & Johnson, and President at Johnson & Johnson Innovation - JJDC, Inc. He also held positions as Director at CVRx, Inc. and International Biomedical Research Alliance, Member-Supervisory Board at Crucell NV, and Vice President-Licensing at Ortho Pharmaceutical Corp.Heyman received a graduate degree from Katholieke Universiteit Leuven and the University of Antwerp. |
| Xiao Hui Ji |
Xiao Hui Ji is the Chairman & Chief Executive Officer of Elpiscience Biopharma Ltd., a company he founded in 2017. He is also currently serving as an Independent Director at Legend Biotech Corp. since 2020. Previously, Dr. Ji held the position of Chief Executive Officer at PharmaLegacy Laboratories (Shanghai) Co., Ltd. He was also a Director at The BayHelix Group from 2008 to 2013 and Vice President-Business Development at Roche Holding AG from 2013 to 2016. From 2017 to 2020, he worked as a Partner at LAV Management Co., Ltd. In terms of education, Dr. Ji holds an MBA from The University of Chicago and has completed graduate studies at The University of Sheffield and China Medical University. |
